Mirvaso Europska Unija - hrvatski - EMA (European Medicines Agency)

mirvaso

galderma international - brimonidin tartrat - bolesti kože - ostali dermatološki pripravci - mirvaso je indiciran za simptomatsko liječenje eritema grudi rosacea kod odraslih pacijenata.

Epiduo 1 mg/g + 25 mg/g gel Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

epiduo 1 mg/g + 25 mg/g gel

galderma international, tour europlaza, 20 avenue andre prothin, la defense 4, la defense cedex, francuska - adapalen benzoilperoksid - gel - 1 mg/g + 25 mg/g - urbroj: 1 g gela sadrži 1 mg adapalena i 25 mg benzoilperoksida

Aklief 50 mikrograma/g krema Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

aklief 50 mikrograma/g krema

galderma international, tour europlaza, 20 avenue andre prothin, la defense 4, la defense cedex, francuska - trifaroten - krema - urbroj: jedan gram kreme sadrži 50 mikrograma trifarotena

Epiduo 3 mg/g + 25 mg/g gel Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

epiduo 3 mg/g + 25 mg/g gel

galderma international, tour europlaza, 20 avenue andre prothin, la defense 4, la defense cedex, francuska - adapalen benzoilperoksid - gel - urbroj: jedan gram gela sadrži 3 mg adapalena i 25 mg benzoilperoksida

Veregen 100 mg/g mast Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

veregen 100 mg/g mast

nordic pharma s.r.o., k rybniku 475, jesenice, Češka - ekstrakt lista zelenog čaja - mast - 100 mg/g - urbroj: 1 g masti sadrži 100 mg ekstrakta (u obliku suhog ekstrakta, rafiniranog) camellia sinensis (l.) o. kuntze, folium (list zelenog čaja) (24-56:1), što odgovara: 55-72 mg (-)-epigalokatehingalata: otapalo kod prve ekstracije: voda

GOLDERM 25% GEL Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

golderm 25% gel

bosnalijek d.o.o., zagreb - prevencija i pomoć pri liječenju neinficiranih, površinskih ozljeda na koži

Protopic Europska Unija - hrvatski - EMA (European Medicines Agency)

protopic

leo pharma a/s - takrolimus - dermatitis, atopic - ostali dermatološki pripravci - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. javlja četiri ili više puta godišnje), koji su imali početni odgovor za najviše šest tjedana terapije, dva puta dnevno masti tacrolimus (mjesta očistili, gotovo izbrisani ili slabo utječe).

Azacitidine Mylan Europska Unija - hrvatski - EMA (European Medicines Agency)

azacitidine mylan

mylan ireland limited - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.

Cosentyx Europska Unija - hrvatski - EMA (European Medicines Agency)

cosentyx

novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - imunosupresivi - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psorijatični arthritiscosentyx, odvojeno ili u kombinaciji sa metotreksatom (mtx), propisan za liječenje aktivnog psorijatični artritis kod odraslih pacijenata, kada je odgovor na prethodna bolest дорабатывая anti-reumatskih lijekovi (dmards) terapija je bila neadekvatna.. Аксиальный спондилоартрит (axspa)ankilozantni спондилоартрит (kao, радиографические osi спондилоартрит)cosentyx indiciran za liječenje aktivnog анкилозирующего спондилита kod odraslih, koji su adekvatno odgovorili na standardnu terapiju. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.